The dynamic regulation of β-cell abundance is poorly understood. Since chromatin remodeling plays critical roles in liver regeneration, these mechanisms could be generally important for regeneration in other tissues. Here we show that the ARID1A mammalian SWI/SNF complex subunit is a critical regulator of β-cell regeneration. Arid1a is highly expressed in quiescent β-cells but is physiologically suppressed when β-cells proliferate during pregnancy or after pancreas resection. Whole-body Arid1a knockout mice were protected against streptozotocin induced diabetes. Cell-type and temporally specific genetic dissection showed that β-cell specific Arid1a deletion could potentiate β-cell regeneration in multiple contexts. Transcriptomic and epigenomic profiling of mutant islets revealed increased Neuregulin-ERBB-NR4A signaling.
Introduction
Understanding how to recover endogenous β-cells in disease might ultimately depend on understanding how β-cell abundance is controlled in the first place. The molecular circuitry that dictates total β-cell mass during development and dynamic physiologic situations such as pregnancy is poorly understood. It is also unclear if the same mechanisms regulate β-cell expansion after injuries and during disease processes. One unexploited therapeutic strategy is to expand endogenous β-cells in type 1 and 2 diabetes, settings in which normal regenerative capacity cannot fully compensate for β-cell loss. Given the importance of dedifferentiation and proliferation in profoundly regenerative organisms such as zebrafish and planaria (Jopling et al., 2011) , it stands to reason that facilitating chromatin state changes that occur physiologically could also increase self-renewal capacity in mammalian tissues. We hypothesized that the mammalian SWI/SNF (mSWI/SNF) ATP-dependent chromatin remodeling complex, known to promote terminal differentiation (Han et al., 2019; Hota et al., 2019; Sun et al., 2016b; Yu et al., 2013; Zhang et al., 2019 Zhang et al., , 2016 and also known to limit regeneration after liver injuries (Sun et al., 2016b) , might operate as a general repressor of regeneration in tissues other than the liver.
Given key similarities between β-cell and hepatocyte self-renewal, we reasoned that mSWI/SNF might also suppress regenerative capacity in β-cells, a centrally important cell type in metabolic disease. mSWI/SNF are large 10-15 component complexes containing a core ATPase (BRG1 or BRM, also known as SMARCA4 and SMARCA2), plus non-catalytic subunits that influence targeting and complex activities (Wu et al., 2009 ) such as the mutually exclusive ARID1A (BAF250A) and ARID1B (BAF250B) subunits, which together define the canonical BAF family of mSWI/SNF complexes. The loss of ARID1A alters the assembly of the ATPase module (Mashtalir et al., 2018) , influencing canonical BAF complex targeting and DNA accessibility, resulting in global changes in gene regulation (Chandler et al., 2013; Kelso et al., 2017; Mathur et al., 2017; Nakayama et al., 2017; Pan et al., 2019; Sun et al., 2018) . How the molecular consequences of mSWI/SNF perturbation relate to physiologic phenotypes and disease outcomes is an active area of exploration.
Intriguingly, ARID1A and other mSWI/SNF components are downregulated during islet expansion, findings shared with other regenerative tissues such as the liver (Sun et al., 2016b) .
We demonstrated that this downregulation is functionally important by using spatially and temporally specific conditional knockout mouse models subjected to multiple types of β-cell injuries. These findings support the idea that physiological events that occur during regeneration can be further amplified to accelerate tissue healing. Molecular dissection of the events occurring downstream of ARID1A loss showed that NRG-ERBB-NR4A signaling activities were increased. Interestingly, the ERBB protein family (EGFR/ERBB1, ERBB2, ERBB3, and ERBB4) of transmembrane receptor tyrosine kinases (RTKs) have been implicated in diabetes (Miettinen et al., 2006; Oh et al., 2011; Song et al., 2016) . Remarkably, SNPs in the human ERBB3 locus are among the strongest signals in T1D GWAS but how these SNPs affect ERBB signalling and β-cell biology were previously unknown (Bradfield et al., 2011; Nikitin et al., 2010; Sun et al., 2016a) . Here, we show that ARID1A-containing SWI/SNF complexes have a major and unexpected role in β-cell regeneration, operating in large part through pathways that were previously implicated by GWAS studies in diabetogenesis. This expands our emerging understanding of mSWI/SNF as a central regulator of tissue regeneration, and underscores the need to understand chromatin remodeling mechanisms that may represent therapeutic targets in regeneration.
Results

Arid1a expression is suppressed during physiologic β-cell expansion
ARID1A-containing SWI/SNF chromatin remodeling complexes (or canonical BAF complexes) drive terminal differentiation and block proliferation by regulating chromatin accessibility at loci targeted by lineage specific transcription factors Spaeth et al., 2019; Vierbuchen et al., 2017) . In the absence of ARID1A, increased liver regeneration and accelerated wound healing were observed (Sun et al., 2016b) . Although the primary mechanism for the homeostatic maintenance of adult β-cells is self-duplication, majority of adult pancreatic β-cells are still mostly in post-mitotic state (Dor et al., 2004; Meier et al., 2008) . We wondered if the inhibition of SWI/SNF activity could increase their proliferative potential. Genes that encode components of the SWI/SNF complex are expressed at high levels in the mouse β-cell line MIN6 and primary pancreatic islets compared to the mouse α-cell line ATC1 and primary hepatocytes ( Figure 1A ). In particular, Arid1a is highly expressed in quiescent β-cells within the islet ( Figure 1B ). Next, we examined Arid1a expression in islets under conditions that demand β-cell expansion, such as pregnancy and 50% partial pancreatectomy (PPx) (Ackermann Misfeldt et al., 2008; Rieck and Kaestner, 2010) . Arid1a mRNA was lower in maternal islets during pregnancy-associated β-cell expansion, and protein levels declined until the time of birth ( Figure 1C,D ) . Similarly, ARID1A protein levels were reduced during regeneration induced by PPx ( Figure 1E ).
We asked if signals known to elicit β-cell hyperplasia can influence the levels of Arid1a mRNA.
We isolated wild-type (WT) mouse islets and treated with glucagon-like peptide-1 (GLP-1), high glucose, insulin-like growth factor-2 (IGF2), and interleukin-1β ( IL-1 β ), all factors known to drive β-cell proliferation (Alismail and Jin, 2014; De León et al., 2003; Gaddy et al., 2010; Hajmrle et al., 2016; Porat et al., 2011) . Each factor suppressed Arid1a mRNA levels in islets, providing a potential molecular rationale for how the suppression of Arid1a during β-cell expansion is linked to upstream signals ( Figure 1F ). These results indicated dynamic regulation of ARID1A and SWI/SNF complex components during β-cell expansion and regeneration, suggesting functional roles during these processes.
Whole-body Arid1a deletion protected against type I diabetes
To determine if ARID1A restrains β-cell mass in adults, we inducibly deleted Arid1a in a whole body " Arid1a KO" mouse strain. Global deletion was induced with tamoxifen in adult Ubiquitin-CreER; Arid1a Fl/Fl ( Ubc-CreER; Arid1a Fl/Fl ) mice ( Figure 2A ). Almost complete absence of the flox band and protein levels were observed ( Figure 2B-D ). Whole body Arid1a KO mice did not show overt signs of disease and appeared to be healthy. At baseline, whole body glucose tolerance was unchanged, indicating that ARID1A is not required for the regulation of glucose homeostasis or uptake under non-injury, basal conditions ( Figure 2E ). To determine if Arid1a KO mice were more able to cope with β-cell destruction in a type 1 diabetes (T1D) model, we subjected mice to streptozotocin (STZ), a chemical that ablates insulin-producing β-cells ( Figure 2A ). After STZ, Arid1a KO mice were almost completely protected against the development of diabetes as measured by fed state glucose levels ( Figure 2F ) and glucose tolerance testing (GTT) ( Figure 2G ). This left the possibility of either insulin secretion or insulin sensitivity changes, particularly because Arid1a was deleted in all tissues. Mice subjected to STZ did not show changes in insulin sensitivity based on insulin tolerance testing (ITT), suggesting no substantial metabolic impact of Arid1a loss on peripheral tissues, despite efficient deletion in those tissues ( Figure 2H ). However, Arid1a KO mice produced higher levels of insulin after glucose administration ( Figure 2I ), suggesting a β-cell mediated mechanism of protection against or response to STZ-induced T1D.
Arid1a deficiency leads to a β-cell-mediated anti-diabetic phenotype
Given that the whole body KO mice have lost Arid1a in multiple cell types, it was possible that non-β-cell autonomous mechanisms might have been at play. In WT mice, ARID1A is expressed in most acinar, all duct, and all islet cells. To rule out potential paracrine or endocrine effects, we used Ptf1a-Cre; Arid1a Fl/Fl mice to induce deletion in non-β-cells in the pancreas.
Ptf1a
is a transcription factor that is expressed in all cell types in the pancreas starting around E9.5 (Kawaguchi et al., 2002) . In Ptf1a-Cre; Arid1a Fl/Fl mice, ARID1A was lost in all acinar and most duct cells but ARID1A protein was retained in the islets, as shown recently (Wang et al., 2019a (Wang et al., , 2019b . GTT did not reveal any differences in glucose clearance efficiency between WT, Ptf1a-Cre; Arid1a +/Fl , or Ptf1a-Cre; Arid1a Fl/Fl mice ( Figure S1A ). Following STZ treatment ( Figure S1B ), there were also no differences in blood glucose measurements over the course of 1 month ( Figure S1C ) , ruling out a potential contribution from acinar or duct cells to the phenotypes observed in whole-body KO mice.
Next, we generated a temporally regulated, β-cell specific model of Arid1a loss. This model allowed us to induce β-cell specific deletion of Arid1a after β-cell injuries, thus giving us the ability to answer questions specifically about β-cell regeneration, rather than cell survival in the presence of injuries. We employed a MIP (Mouse Insulin Promoter)-rtTA; TRE (Tetracycline Responsive Element promoter)-Cre transgenic system to allow such genetic control ( Figure 3A ) (Kusminski et al., 2016) . MIP-rtTA; TRE-Cre; Arid1a Fl/Fl (Arid1a βKO) mice and littermate controls without Cre and/or rtTA were used to model cell-type and temporally specific Arid1a deletion. Notably, some Arid1a floxed band was still present in islets, potentially due to α , δ and γ cell retention of the Arid1a floxed allele ( Figure 3B ). Despite the absence of ARID1A nuclear staining ( Figure 3C ), islet cell morphology was normal. Two weeks post-deletion, the ability to clear glucose after GTT challenge was unaltered ( Figure 3D ), suggesting that there was no change in β-cell function at baseline. Next, both groups of mice were given five doses of STZ (50mg/kg per day x 5 days), then fed doxycycline (1mg/mL) water to conditionally induce Arid1a deletion in the β-cells of the experimental group. β-cell specific deletion of Arid1a after STZ administration prevented the rise of blood glucose to pathological levels ( Figure 3E ), and reduced the profound weight loss associated with T1D ( Figure 3F ). In the setting of STZ, Arid1a βKO showed higher insulin levels than control mice. Not surprisingly, insulin levels were still lower in the STZ treated Arid1a βKO group than uninjured WT mice since STZ was still able to ablate a subset of β-cells ( Figure 3G ). These data showed that Arid1a deficiency in β-cells was sufficient to preserve insulin production in response to STZ-induced T1D.
Arid1a loss results in increased β-cell survival and proliferation
We examined islets before and after STZ injury. Insulin staining in WT and Arid1a βKO islets at baseline showed no differences. Thirty days after STZ, Arid1a βKO mice had more β-cells than did WT mice ( Figure 4A ). In addition, WT mice showed considerable α -cell expansion as marked by glucagon staining ( Figure 4B ). Because resistance to diabetes could have been mediated by either a failure to lose β-cells or an increased ability to regenerate β-cells, we examined proliferation in the insulin expressing β-cell compartment. Arid1a deficient β-cells had greater numbers of Ki-67 positive cells. In the WT setting, a majority of the proliferating cells were positioned in the islet periphery, which is the non-insulin expressing compartment ( Figure   4C ,D ). We then wondered whether the observed increase in proliferation after STZ had any effect on islet number or area. Although we did not detect any increase in the number of islets per unit of pancreas area ( Figure 4E ), there was a trend towards increased individual islet area (p=0.06) ( Figure 4F ) in βKO mice 3 weeks after STZ.
Given the remote possibility that Arid1a deficient β-cells could be protected from T1D due to a lack of STZ induced destruction rather than increased regeneration, we also performed PPx, a surgical assay that does not rely on the ability of cells to metabolize chemical toxins such as STZ. PPx leads to β-cell proliferation that compensates for overall islet loss. Six days after resection, the islets from regenerated pancreata of βKO mice showed a significant increase in β-cell proliferation as measured by Ki-67 positive cell number within the insulin expressing compartment ( Figure 4G ). In summary, Arid1a loss in β-cells did not constitutively enforce islet overgrowth in the absence of injury but increased proliferation after chemical and surgical injuries.
Phenotypes associated with Arid1a loss are dependent on EGF/Neuregulin hyperactivation
To probe the transcriptional programs associated with Arid1a deletion, we performed RNA-seq on islets from control and KO mice, before and after pancreatectomy. Of 2796 differentially-expressed genes, 1586 were up and 1210 were downregulated ( Figure 5A ). Gene Set Enrichment Analysis (GSEA) performed on differentially expressed genes showed that genes involved in the neuregulin (NRG) and epidermal growth factor (EGF) pathways were collectively overproduced in KO islets ( Figure 5B & Figure 5A right inset ). EGF and NRG are the ligands that activate ERBB family of RTKs. Binding of the EGF family growth factors leads to dimerization and phosphorylation of RTKs which leads to the activation of ERK1/2 and phosphatidylinositol 3-kinase (PI3K) signaling pathways (Yarden and Sliwkowski, 2001) .
To functionally interrogate the transcriptomic findings, we performed shRNA knockdown of Arid1a in BTC6 and MIN6 immortalized β-cell lines to determine if Arid1a loss might cause increased dependency on NRG/EGF signaling. Arid1a knockdown in BTC6 and MIN6 caused increased phospho-EGFR (p-EGFR) after EGF ligand exposure, indicating potentiation of the pathway ( Figure 5C ). In addition, EGFR/ERBB inhibition with the small molecule inhibitors erlotinib and canertinib were able to ablate p-EGFR in the presence of EGF ( Figure 5D ). Similar proliferative phenotypes were confirmed with Arid1a shRNA in MIN6 cells and these small molecule inhibitors selectively abrogated the hyperproliferation associated with Arid1a knockdown ( Figure 5E ).
To corroborate the shRNA results using another in vitro model, we generated Arid1a deficient MIN6 β-cells using CRISPR. Multiple single cell MIN6 clones for each genotype were expanded and confirmed for Arid1a loss ( Figure 5F ). Similar to β-cells from mouse islets, Arid1a KO MIN6 clones grew more rapidly than Gal4 targeted control clones ( Figure 5G ). Genes identified in the RNA-seq experiment were also upregulated in KO vs. control islets ( Nr4a1, Nr4a2, Srf, JunB ;
see Figure 5H ). Collectively, these data show that Arid1a loss in β-cells causes a preferential dependency on ERBB signalling.
To determine if differentially expressed genes from the RNA-Seq analysis also showed changes in epigenetic marks, we performed H3K27 acetylation (H3K27ac) ChIP-seq. Sites marked by
H3K27ac were clustered into groups that increased or decreased in H3K27ac in response to Arid1a deletion ( Figure 5I ). Interestingly, many sites increased in H3K27ac abundance in the Arid1a heterozygous and homozygous clones (clusters 3 and 4). The clusters containing sites that changed in H3K27ac occupancy upon Arid1a loss were largely composed of sites at distal regions ( Figure 5J ) , which is consistent with the disruption of canonical BAF complexes (Kelso et al., 2017; Mathur et al., 2017; Vierbuchen et al., 2017) . Sites that increased in H3K27ac upon Arid1a loss included Nrg4 and Egfr , consistent with transcriptional hyperactivation in the Arid1a -deficient setting ( Figure 5K ) . GO biological processes associated with increased acetylation of H3K27 in the Arid1a knockout populations in clusters 3 and 4 contain terms involving glucocorticoid biosynthesis and hormone metabolism, and the associated mouse phenotypes included abnormal insulin secretion and pancreas secretion ( Figure S2A and Figure S2B ). These observations are consistent with differential regulation of pathways affecting glucose metabolism and insulin secretion in KO mouse β-cells.
To challenge the idea that Arid1a deletion causes more proliferation through the preferential promotion of ERBB signaling as opposed to a more generalized activation of multiple mitogenic signal pathways, we performed a small molecule screen to identify pathways that Arid1a KO cells are more dependent on for growth and survival. We screened 300 kinase inhibitors on previously generated immortalized H2.35 cells isogenic for Arid1a deletion ( Figure S3A ).
Interestingly, ERBB family inhibitors were significantly enriched among treatments that induced the most prominent reductions in cell viability (P-value = 5.8e-6). There were 3 ERBB family inhibitors (Afatinib, WZ8040, canertinib) among the top 10 kinase inhibitors associated with the highest reduction of growth/viability in Arid1a KO cells ( Figure S3B ). Together with the islet transcriptome data, these observations established a strong functional connection between ARID1A and ERBB.
ERBB3 overexpression independently increases β-cell regeneration
In order to perform gain-of-function studies for ERBB signalling, we first asked which ERBB receptor loci ARID1A might be acting through. ChIP-seq data on human liver cell line HepG2 showed binding of ARID1A and core SWI/SNF component SNF5 on the promoters of ERBB2
and ERBB3 ( Figure 6A ) (Raab et al., 2015) . In addition, multiple human GWAS studies have shown strong associations between a SNP (rs2292239) in ERBB3 and T1D (Barrett et al., 2009; Kaur et al., 2016; Sun et al., 2016a; Todd et al., 2007) . Based on these observations, we reasoned that ARID1A could have a genetic interaction with ERBB3 . Because it is still unknown whether or not an increase or decrease of ERBB3 in β-cells or other tissues is protective in human T1D, we generated a β-cell specific human ERBB3 overexpression mouse model ( MIP-rtTA; TRE-ERBB3 ) ( Figure 6B ). Strikingly, inducible overexpression of ERBB3 alone was sufficient to mediate resistance to STZ-induced T1D ( Figure 6C ). This is the first functional confirmation of an effect for ERBB3 on a T1D model.
To determine if there is an epistatic relationship between ERBB3 and Arid1a , we genetically manipulated both genes in vivo. We hypothesized that if the two genes act via distinct pathways, ERBB3 overexpression in an Arid1a deficient background would have a synergistic effect ( Figure 6D ), whereas if both genes are within the same pathway, then there would be little to no additive effect. While mice with either β-cell specific ERBB3 overexpression or Arid1a loss showed protection against STZ-induced diabetes, simultaneous perturbations did not synergize to increase the protective effect ( Figure 6E ). The lack of a synergistic effect suggests that either these genes are acting in the same pathway, or that the effects are individually saturated. These results for the first time validate the human GWAS signals for ERBB3 in an animal model and support the hypothesis that Arid1a loss is operating through increases in ERBB signaling.
Pan-ERBB and NR4A1 inhibition ablated the Arid1a KO phenotype in vivo
We sought to determine whether pro-proliferative effects of Arid1a loss were mediated through ERBB activation in vivo as well as in vitro. We first tested the in vivo relevance of these results by examining whole body Ubc-CreER; Arid1a WT and KO mice described earlier. After STZ mediated islet ablation, mice were given daily doses of canertinib, an intervention that abolished the anti-diabetic effects of Arid1a loss ( Figure 7A , compare to Figure 2F which did not include canertinib). We reasoned that ERBB inhibition in the STZ model could have been influenced by cell death in addition to proliferation, so we also performed the PPx assay to assess β-cell proliferation after surgical injury. Here, β-cell specific Arid1a deletion was induced one week before PPx and drug treatments were started one day before and continued until 6 days after PPx, which is the apex for β-cell proliferation (Peshavaria et al., 2006) . The increase in Because ARID1A likely influences a large network of genes that regulate differentiation and regenerative capacity, we next asked if other genes downstream of ERBB signaling exert the effects of Arid1a loss. To further examine important functional networks resulting Arid1a KO phenotype, a protein-protein interaction network of overexpressed genes from the RNA-seq data was created using the STRING database (Szklarczyk et al., 2015) . This interaction network showed that the SRF/JUN/FOS/EGR1 transcription factors and the NR4A family of nuclear receptor transcription factors were tightly connected and clustered together ( Figure 7D ).
Indeed, these genes also came up under the GSEA datasets that were classified as "EGF/NRG1 signaling up" ( Figure 5A ) suggesting that they are downstream of ERBB signaling.
The overexpression of these transcription factors were previously established as one of the hallmarks of immature, proliferative β-cells (Zeng et al., 2017) . We validated higher protein levels of c-FOS and p-NR4A1 in KO islets ( Figure 7E ). We then asked if ARID1A relays its effects in part through NR4A1 in vivo by treating mice that had undergone PPx with an NR4A1
antagonist (C-DIM8), in a similar fashion as the canertinib experiments. C-DIM8 also abolished the increased proliferation normally seen in Arid1a KO β-cells ( Figure 7B, bottom row & 7C ), suggesting that increased NR4A1 activity is additionally required for the phenotypic effects of Arid1a loss.
Discussion
Preserving or replenishing endogenous pancreatic β-cells is a major challenge in diabetes. To ultimately meet these goals, there is a need to understand the factors limiting β-cell proliferation.
Although engineering strategies such as inducible pluripotent stem cell to β-cell conversion or the transdifferentiation of other cell types to β-cells are emerging (Aguayo-Mazzucato and Bonner-Weir, 2018) , targeting endogenous regeneration of β-cells has potential advantages since this occurs in development, pregnancy, and obesity to meet increased physiological demands for insulin production. Here, we have identified Arid1a as a factor whose suppression is required for gestational β-cell expansion and is sufficient for β-cell replenishment after multiple pancreatic injuries. Previous studies have shown that BRG1 and BRM-containing Vitamin D ligand causes the Vitamin D receptor to interact with an active BRD7/pBAF rather than an inactive BRD9/ncBAF complex, which reduces β-cell failure and slows diabetes progression . Our study is the first to highlight Arid1a and SWI/SNF as an important epigenetic node that regulates the regenerative capacity of β-cells.
By functionally validating EGF/NRG1 signaling as a critical effector of ARID1A suppression, we connected two previously unrelated, but prominent regeneration networks. EGF signaling is known to be important for liver, heart, and pancreas regeneration (D'Uva et al., 2015; Gemberling et al., 2015; Song et al., 2016; Sun et al., 2016b) . GWAS studies implicated ERBB3
as one of the most significant T1D gene loci, but it is not clear if ERBB3 expression is positively or negatively influencing T1D risk, and if ERBB3 is acting in β-cells, immune cells, or peripheral tissues (Barrett et al., 2009; Kaur et al., 2016; Sun et al., 2016a; Todd et al., 2007) . For the first time, we determined that ERBB3 overexpression in β-cells is sufficient to protect against diabetes. The fact that overexpression did not add to the protective phenotype of Arid1a deletion is consistent with the idea that ARID1A loss acts through ERBB signaling.
Mechanistically, our results implicate a network of EGF/NRG1 signaling genes. These include Nr4a nuclear receptor genes and a set of nutrient-responsive immediate early genes ( JunB , Fos , Egr1 ) and their upstream activator Srf (Mina et al., 2015) . Interestingly, EGR binding sites represented the most dynamic chromatin regions during whole body regeneration of Hofstenia miamia , an acoel worm that is capable of whole body regeneration. In these worms, EGR is essential for regeneration through its activities as a pioneer factor that directly regulated wound-induced genes including the EGFR ligands nrg-1 and nrg-2 (Gehrke et al., 2019) . In addition, Zeng et al. recently used single cell transcriptomics to categorize β-cells from less to most mature. They showed that Srf / JunB / Fos / Egr1 were among the most downregulated genes during postnatal β-cell maturation and comprise a signature of less mature, proliferative β-cells.
Importantly, overexpression of upstream activator Srf in islets did not impair insulin secretion (Zeng et al., 2017) . Our data suggest that ARID1A containing complexes may negatively regulate this larger network of pro-regeneration genes. Importantly, β-cells without ARID1A are poised for proliferation while still able to maintain insulin production.
Our study highlights targets that could be investigated for their therapeutic potential in future studies. In contrast to the majority of nuclear receptors, the NR4A family of nuclear receptors do not have an identified physiological ligand, therefore their activity is mainly regulated at the level of protein expression and post-translational modifications (Safe et al., 2016) . However, there is a agonist, Cytosporone-B, that can selectively increase the transcriptional activity of Nr4a 1 (Zhan et al., 2008) . Whether this agonist could be utilized to improve the regenerative potential of β-cells is an area of interest. A more direct way to tackle this problem would be to use specific inhibitors targeting ARID1A or BAF complexes. There is a major interest in the field to develop small molecules to manipulate activities of SWI/SNF complex, and if successful, it will be interesting to determine if such inhibitors might be effective in diabetes. 
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and material requests should be directed to Dr. Hao Zhu ( Hao.Zhu@utsouthwestern.edu ).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice. All experiments on mice were approved by and handled in accordance with the guidelines of the Institutional Animal Care and Use Committee at UTSW. All experiments were performed in in age and gender controlled fashion. Male mice were used for STZ experiments. The transgenic mouse lines used are as follows and described before: Arid1a floxed mice (JAX stock #027717) (Gao et al., 2008) , Ptf1a-Cre (Kawaguchi et al., 2002) , MIP-rtTA (Kusminski et al., 2016) , TRE-Cre (JAX 006234) (Perl et al., 2002) . TRE-HER3 mouse line was generated by 
METHOD DETAILS
Mouse pancreatic islet isolation and dispersion of islets. Islet isolation was done as described previously (Zmuda et al., 2011) Streptozotocin (STZ) injury. Mice were fasted for 4-6 hours prior to STZ injection. STZ (Sigma-Aldrich S0130) was dissolved in sodium-citrate (Sigma-Aldrich S4641) solution to a final concentration of 10 mg/ml freshly 10-15 min before the injection. Sodium-citrate solution was prepared by dissolving 1.47 gram of sodium-citrate powder in 50 ml ddH2O, and adjusting the pH to 4.5. Prepared STZ solution was injected via intraperitoneal injection. Different dosage was used for different strain backgrounds as indicated in the figure legends since response to STZ is strain dependent.
Glucose tolerance test (GTT). After 16 hours fast, blood glucose was measured using a glucometer from tail tip blood before and multiple times within 2 hours of intraperitoneal injection of 2g/kg D-(+)-Glucose (Sigma Aldrich # G7528).
Insulin tolerance test (ITT). After 6h fast, blood glucose was measured before intraperitoneal injection of insulin (0.75 mU/g body wt) and then 30, 60, 90 and 120 min after injection.
Partial pancreatectomy (PPx). PPx was performed as described (Martín et al., 1999) except that mice were not fasted overnight. 
RNA
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq Analysis. RNA-Seq analysis was performed as described before (Celen et al., 2017) .
Briefly, adaptors and low quality sequences (Phred<20) were removed by trimming raw sequencing reads using galore package ( http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ ). The sequence reads were aligned to the GRCm38/mm10 with HiSAT2 (Kim et al., 2015) . After duplicates removal by SAMtools (Li et al., 2009) , read counts were generated for the annotated genes based on GENCODE V20, using featureCounts (Harrow et al., 2012; Liao et al., 2014) . Differential gene expression analysis was performed on edgeR, using FDR < 0.05 as cutoff (McCarthy et al., 2012; Robinson et al., 2010) . Heatmaps to visualize the data were generated by using GENE-E (Robinson et al., 2010) .
GSEA . GSEA was used to determine significantly enriched gene sets. To perform GSEA analysis using RNA-seq data from WT and Arid1a KO islets, raw read counts from each sample were converted to cpm value (count per million) using the cpm function within edgeR R package. GSEA analysis was performed with a pre-ranked gene list by log fold change. GSEA was then performed against hallmark gene sets using default parameters (http://software.broadinstitute.org/gsea/index.jsp).
ChIP-seq Data Processing and Analysis. Sequencing of ChIP-seq samples was carried out using the Illumina NextSeq technology, and reads were demultiplexed with the bcl2fastq software tool. Read quality was evaluated by FASTQC, and read alignment to the hg19 genome was executed with Bowtie2 v2.29 in the -k 1 reporting mode (Langmead and Salzberg, 2012) . Narrow peaks were detected using MACS2 v2.1.1 with a q-value cutoff of 0.001 and input as controls . Output BAM files were transformed into BigWig track files using the "callpeak" function of MACS2 v2.1.1 with the "-B --SPMR" option followed by the use of the BEDTools (Quinlan and Hall, 2010) "sort" function and the UCSC utility "bedgraphToBigWig". BigWig track files were then input in IGV v2.4.3 for visualization. Heat maps were generated using ngsplot v2.61, which was also used to perform K-means clustering (Shen et al., 2014) . Cis-regulatory function analysis was carried out using the GREAT online software suite (Argiras et al., 1987) .
Statistical analysis . Variation is indicated using standard error presented as mean ± SEM.
Two-tailed Student's t -tests (two-sample equal variance) were used to test the significance of differences between the two groups. Statistical significance is displayed as * (P < 0.05), ** (P < 0.01), *** (P < 0.001), ****(P < 0.0001). Statistical analyses were performed using GraphPad Prism unless otherwise indicated. Mice from multiple litters were used in the experiments. In STZ follow up experiments, mice were occasionally excluded from the analysis due to death.
DATA AND CODE AVAILABILITY
All sequencing data have been deposited in the GEO with the accession number (pending). x 2 days, diabetes was induced by injecting 50 mg/kg STZ IP for 5 consecutive days.
FIGURES AND LEGENDS
B.
Genotyping of tail and islets to assess the recombination at the Arid1a Fl/Fl locus.
C. Western blot assessing the reduction in ARID1A protein levels. F. Individual islet area (n = 4 WT mice and 6 Arid1a βKO mice, at least 10 islets were measured for each mouse).
G.
Ki-67+ cell number/insulin+ area in islets from regenerated pancreata 6 days after PPx (n = 7 WT and 5 Arid1a βKO mice, values from~10 islets per mice were calculated and averaged to get a single data point in the graph). A. Binding of ARID1A and SNF5, a core SWI/SNF subunit, to the ERBB3 locus in HepG2 cells (ChIP-seq data from (Raab et al., 2015) ). A. Cis-regulatory function analysis by GREAT on sites within Cluster 3 (increased H3K27Ac
in Arid1a HET condition) given as GO processes and mouse phenotypes.
B. Cis-regulatory function analysis by GREAT on sites within Cluster 4 (increased H3K27Ac
in Arid1a KO condition) given as GO processes and mouse phenotypes. Figure S3 . Kinase inhibitor screen in H2.35 cells shows that Arid1a deficient cells are more sensitive to cell growth inhibition induced by ERBB inhibitors than WT cells.
A. Relative cell growth (KO vs WT). About 300 kinase inhibitors were used in this screen.
Each gray dot corresponds to relative growth of Arid1a KO vs. WT cells in the presence of a non-ERBB kinase inhibitor, whereas each red dot corresponds to an ERBB family kinase inhibitor. 
B.
